Flash Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Flash Therapeutics's estimated annual revenue is currently $9.3M per year.
- Flash Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Flash Therapeutics has 60 Employees.
- Flash Therapeutics grew their employee count by 0% last year.
Flash Therapeutics's People
| Name | Title | Email/Phone |
|---|
Flash Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Flash Therapeutics?
Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform and bioproduction technologies. The Company is built around the Vectalys lentiviral platform, which includes its patented non-integrative LentiFlash® technology, and integrative lentiviral vectors. By providing efficient, transient and short-term RNA delivery technology, LentiFlash® is suitable for gene editing and other advanced therapeutic approaches. When stable DNA expression is needed (e.g. immunotherapy such as CAR T cells), integrative lentiviral vectors will be the delivery method of choice. Both technologies benefit from novel production and purification processes developed and continually optimized since 2005. Flash Therapeutics is advancing two business lines: - Therapeutic development based on LentiFlash®, with internal programs for blood and liver diseases; - Development and manufacturing support to companies worldwide pursuing lentiviral delivered therapies. Flash Therapeutics was established in 2018 through the merger of FlashCell, a privately held company developing LentiFlash®, based RNA therapeutics; and Vectalys, a leading privately held 13-year old lentiviral vector manufacturer.
keywords:N/A
N/A
Total Funding
60
Number of Employees
$9.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Flash Therapeutics News
The flash funding proposals received this spring were fascinating. It's impressive to see so many students and faculty at UVA focused on making...
Other Companies in Toulouse
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 61 | 30% | N/A |
#2 | $16.4M | 63 | -9% | N/A |
#3 | $8.4M | 64 | 12% | N/A |
#4 | $19.5M | 67 | 16% | N/A |
#5 | $8.9M | 68 | -7% | N/A |